Efficacy of ertapenem for secondary treatment of diabetic foot infections

Wounds

Volumn 22, Issue 6, 2010, Pages 158-160

  Shklyar, Arkady ^a   Miller, Edward B ^a   Landau, Zvi ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954059110     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39(7):885-910. (Pubitemid 39328144)
2. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial. Lancet. 2005;366(9498):1695-1703.
3. Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA. Comparative costs of ertapenem and piperacillin/tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm. 2007;64(10):1080-1086. (Pubitemid 46801540)
4. Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007;44(4):562-565.
5. Sotto A, Lemaire X, Jourdan N, Bouziges N, Richard JL, Lavigne JP. In-vitro activity of ertapenem against strains isolated from diabetic foot infections. [Article in French]. Med Mal Infect. 2008;38(3):146-152.